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 Introduction : The novel coronavirus disease (COVID-19) 
pandemic, caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), remains a global challenge 
since December 2019 cause by its severe symptoms and 
high mortality rate. Some comorbidities are associated 
with clinical outcomes in COVID-19 patients, one of them 
is cardiovascular disease, including coronary heart 
disease (CHD). Statins are popularly used as the lipid 
controller in CHD patients. Not only controlling the lipid 
profile, statins also can reduce the inflammation process 
in COVID-19 patients. This review aims to determine the 
activity of statins and its potential to improve the clinical 
manifestation of COVID-19 patients with CHD. Methods : 
The method used in this paper is to examine and review 
the literature journal that has been published last 10 years. 
Results : Recent studies have shown that statins capable 
to control the lipid, also lowering the LDL cholesterol and 
increasing the HDL cholesterol. And other trials have 
shown that statin also have ability to reduce the 
inflammation and inhibit further cell damage by binding 
mpro, a protease produced by SARS-COV2. 
Conclusions:  Based on those studies, we conclude that 
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Corona Virus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) infection that leads to several symptoms such 
as fever, dry cough, tachypnea, (1) starting from second day to the 14th after the first 
exposure(2). COVID-19 was first discovered in December 2019 in Wuhan, China and has 
been spread to more than 180 countries. (3) The first COVID-19 cases in Indonesia were 
identified on March 2nd 2020 and the positive-confirmed cases of COVID-19 continues 
to occur rapidly by then.  
In Indonesia, thousands cases of COVID-19 have been identified. (4) Several 
studies have found that poor clinical symptoms of COVID-19 were caused by cytokine 
storm phenomenon that is characterized by high levels of pro-inflammatory cytokines 
such as Tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6), and other pro-
inflammatory cytokines  (5)(6)  
Several studies have reported that some comorbids such as chronic obstructive 
pulmonary disease (COPD), hypertension, cardiovascular diseases, and brain disorders 
can affect the condition of COVID-19 patients. Patients with any comorbidity yielded 
poorer clinical outcomes than those without.(2)  
Coronary heart disease (CHD) is one of the comorbidities that can worsen clinical 
manifestation in COVID-19 patients. (7) This disease is caused by atherosclerotic plaques 
due to high level low density lipoprotein (LDL) cholesterol.(8) Dyslipidemia becomes one 
of the conditions that can increase cardiovascular disease incidence, including coronary 
heart disease that can worsen clinical manifestation in COVID-19 patients. So this makes 
regular lipid control necessary to evaluate in COVID-19 patients, especially for those with 
cardiovascular comorbidity.(9) 
Statin is one of the popular medical therapy options to treat patients with coronary 
heart disease  by lowering LDL cholesterol.(10) Besides lowering LDL cholesterol level, 
statins can also suppress the inflammation, including in COVID-19 patients. (11) In 
addition, statins can increase the level of High Density Lipoprotein (HDL) cholesterol and 
it can bind to SARS-CoV-2 Main proteinase (SARS-CoV-2 M Pro), a protease enzyme 
of SARS-CoV-2 that can cause tissue damage. (12) Those evidences support the potential 
effect of statin as an adjuvant therapy to control lipid profile and to improve clinical 
outcomes in COVID-19 patients with coronary heart disease. 
 
2.  METHODS  
In this literature review, the authors searched Google Scholar and PubMed 
databases using some keywords:  COVID-19, statin, and coronary heart disease. The 
latest journals are collected and then the selection process is based on chosen topic and  
the inclusion and exclusion criteria are considered to sort the results.  
The inclusion criterias used in this study are: references that match with keywords 
and published in the last 10 years. Exclusion criteria are limitations in accessing journals. 
After finding the criterias, the contents of selected journals were used as references in 
statins have the potential effect as adjuvant therapy for 
clinical improvement in COVID-19 patients with CHD.  
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compiling this literature review. In total, there are 42 journals used as references in this 
study. 
 
3. COVID-19 AND POTENTIAL OF ROSUVASTATIN IN CORONARY HEART 
DISEASE PATIENTS 
3.1. COMORBIDITY LEADS TO CLINICAL DETERIORATION OF COVID-19 
The COVID-19 pandemic presents an unprecedented challenge to public health 
due to its high morbidity and mortality rates. Currently, more than 180 countries have 
reported 10,533,779 COVID-19 cases with 512,842 deaths on the 2nd of July 2020. 
SARS COV-2 has infected various groups of ages, ethnicities, and sexes that spreads 
rapidly among the community. (3) 
COVID-19 has a broad spectrum of clinical manifestations, ranging from 
asymptomatic to severe symptoms. There is 80% of mild to moderate COVID-19 cases 
globally, 13,8% of severe cases, and 6,1% of critical cases. Most of infected patients 
experience mild respiratory symptoms such as dry cough and sneezing,  to the most 
severe symptoms such as difficulty breathing or shortness of breath. Other symptoms 
that can be found in COVID-19 patients are productive cough, sore throat, myalgia or 
arthralgia, chills, nausea or vomiting, nasal congestion, hemoptysis, conjunctival 
congestion, abdominal pain, and diarrhea. (13)   
The initial course of COVID-19 begins with incubation period that lasts for about 
3-14 days. The white blood cell count and lymphocytes are still normal or can be slightly 
decreased in the early period of COVID-19. In this period, most of patients usually do 
not show any clinical symptoms. SARS-COV-2 enter host cells via the angiotensin-
converting enzyme 2 (ACE2) receptor, which is expressed in various human organs, 
include respiratory tract, gastrointestinal tract, and heart. Symptoms found in this phase 
are relatively mild. The second wave of symptoms occurs within four to seven days  after 
the initial symptom. Difficulty of breath will be experienced by the patients in this phase 
as a result of lesions in lung parenchyma. Lymphopenia also can be found in this phase. 
Various inflammation markers and hypercoagulopathy tends to increase in this phase. 
Uncontrolled or unresolved inflammation can trigger cytokine storm that can lead to acute 
respiratory distress syndrome (ARDS), sepsis, and other complications.(13)   
The pathophysiology of COVID-19 infection is not fully understood yet. Some 
studies have shown that the spike protein of SARS-COV-2 plays an important role in the 
viral invasion to target cells through Angiotensin Converting Enzyme 2 (ACE2) receptor 
as the  port d’ entree.(14) One of principal mechanism of the clinical deterioration in 
COVID-19 patients is cytokine storm phenomenon. This mechanism is supported by 
several studies that shows increasing level of some pro-inflammatory cytokines in 
patients with severe symptoms compared to patients with mild to moderate symptoms. 
(5)(6)  
In the study of Bo Diao et al , it was found that increasing level of Interleukin-6 
(IL-6), Tumor Necrosis Alpha (TNF-α), and IL-10 in COVID-19 patients was directly 
comparable to the demand of patient for intensive care. (5). Other study by Guang Chen 
et al also has stated  that the level of pro-inflammatory cytokines such as IL-6, IL-10, and 
TNF-α was higher in COVID-19 patients with severe symptoms than in patients with 
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moderate symptoms.(6). These two studies confirmed that cytokine storm may contribute  
in clinical deterioration of COVID-19 patients.  
SARS-CoV-2 infects host cells by binding to the ACE-2 receptor then cause 
aggressive inflammatory response that leads to cytokine storm. After entering host cells, 
SARS-CoV-2 will release its RNA and begin to replicate. After replicating, new viruses 
will be released. The viral antigen will be recognized by the immune system, then trigger 
the response of Natural Killer (NK) cells and CD8 cytotoxic cells  through major 
histocompatibility (MHC). Once this process occurs, pro-inflammatory cytokines will be 
produced and lead to cytokine storm. (15) 
In addition to the pathogenicity of COVID-19, some comorbidities also affect the 
clinical manifestation of COVID-19 patients. Several studies have reported that COVID-
19 patients with comorbidity show worse clinical condition with higher mortality rate. One 
study have shown that comorbidity is common (57,7%) among individuals with COVID-
19. Patients with comorbid disease show more clinically fatal,  84,1% of patients have at 
least one comorbid disease.(3)     
Comorbidities such as hypertension, COPD, cardiovascular disease, and 
diabetes are at risk to trigger clinical deterioration in patients with COVID-19. The United 
States was reported as a country with highest mortality rate worldwide with the top five 
comorbidities among the death cases of COVID-19: hypertension (55,4%), diabetes 
mellitus (37,3%), hyperlipidemia (18,5%), and coronary heart disease (12,4%) (2) 
 
3.2. COVID-19 WITH CORONARY HEART DISEASE 
 Cardiovascular disease plays a role in increasing the risk of morbidity and 
mortality  in patients with COVID-19 (30) Coronary heart disease is one of the major 
comorbidity that can worsen the clinical manifestation of COVID-19. In China, 14,2% of 
44.672 confirmed COVID-19 patients have coronary heart disease. It was also reported 
that 5,8% of patients with severe symptoms had history of coronary heart disease 
compared to 1,8% patients with mild to moderate symptoms. Previous studies have also 
reported that coronary heart disease has identified as the 4th highest comorbidity in 
COVID-19  (7) (16)  
Several studies have shown the high risk of clinical deterioration in COVID-19 
patients with coronary heart disease. (17) The acute systemic inflammatory response and 
large amount of pro-inflammatory cytokines in COVID-19 patients with coronary heart 
disease can trigger plaque rupture, thrombus formation, and coronary varcular spasm 
that leads to myocardial infarction. Aggrasive inflammation will stimulate macrophages 
to produce collagenase, an enzyme that can degrade collagen which is one of the main 
components of atherosclerotic plaqu which is normally found in blood vessels, including 
coronary arteries. After the atherosclerotic plaque inside coronary artery ruptures, 
thrombus can easily form. Besides that, activated macrophage will produce tissue factors 
which are strong procoagulant that will surge the thrombus formation. Furthermore, 
SARS-CoV-2 can also cause direct damage to the endothelium dan vasculature, leading 
to force the thrombus formation. It is supported by several metalloproteinases that are 
related to cytokines recruitment and inflammation that will basically mediated in coronary 
heart disease. Combination of these processes lead to worse clinical outcomes in 
COVID-19 patients with coronary heart disease.(18)  
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3.3. STATIN AS A LIPID STABILISATOR FOR COVID-19 PATIENT WITH 
CORONARY HEART DISEASE   
Coronary heart disease is triggered by atherosclerotic plaque that causes 
obstructive coronary artery and block the blood supply to the myocardium. This 
atherosclerotic plaque is built up  because of the high level of LDL cholesterol which 
transport lipid from liver to peripheral tissues and the low level of High-Density 
Lipoprotein (HDL) cholesterol which transport lipid from peripheral tissues to liver. This 
plaque formation leads to myocardial hypoperfusion and infarction (8)(19) 
The use of statin is one of optional medical therapy in the treatment of coronary 
heart disease globally, it becomes the first line lipid-lowering agent. (10) Besides lowering 
the level of LDL, its other target in controlling lipid is to increase the level of HDL  in 
patients with coronary heart disease. Statins reduce the level of LDL by inhibiting the 
HMG CoA reductase, an enzyme which is important in producing LDL. The inhibition of 
HMG CoA reductase will reduce the production of cholesterol in the liver and reduce the 
level of cholesterol in endoplasmic reticulum. This will result in the translocation of Sterol 
Regulatory Element Binding (SREB) from the endoplasmic reticulum to the golgi 
apparatus. SREB clevage is caused by some proteases and translocated to the nucleus 
and it will activate the transcription factors for some genes such as HMG CoA Reductase 
and LDL receptor genes that stimulates LDL receptors in the liver. Along with the 
increase of LDL receptors, the clearance of Apoliporotein A dan B which containing LDL 
dan VLDL will increase and affect the level of LDL in plasma. (20) (31) This will reduce the 
formation of atherosclerotic plaque in blood vessels. Besides lowering LDL level, statin 
also has the ability in inducing the level of HDL by enhancing the activation of  
peroxisome α proliferator receptor. (21) (32) (33) (34) 
Moreover, statins can also prevent atherosclerotic plaque rupture that is common 
in COVID-19 patient with coronary heart disease. Statins have a mechanism of action 
that can reduce the production o Nitric Oxide Synthase (NOS) in the endothelium that 
can trigger inflammation and atherosclerotic plaque rupture in the vascular endothelium, 
including in the coronary arteries. Statin also have the ability in stabilizing atherosclerotic 
plaque and preventing the rupture. (40)(41) 
Several studies have demonstrated the effectiveness of statin in combating virus 
infection and its potential mechanism. In some virus infection, statin-induced reduction 
of cholesterol in the plasma membrane will supress the viral titer and inhibit the virus to 
invade the cells. These data indicate that cholesterol can also bring an effect on the early 
stages of infection. The virus will bind to the specific receptor that are concentrated in 
lipif rafts, an area of plasma membrane that has large amount of cholesterol.  
Statins can reduce the percentage of cholesterol in the cell membrane, affecting 
receptor binding and altering the adhesion of viral agents into the host cells significantly. 
Lipid rafts are also involved in virus replication because it can concentrate the viral 
replication factors. (35) Lipid rafts with high concentrated cholesterol provide a platform for 
focusing ACE2 on host cell membrane by facilitating the binding of COVID-19 spike 
protein in order to invade the host cells. Statin is potential to be the lipid stabilitator as 
well as an antiviral for COVID-19 patients with coronary heart disease because of its 
therapeutic target is to disrupt the lipid rafts (36)    
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3.4. STATIN AS ANTI-INFAMMATORY AGENT FOR COVID-19 PATIENTS WITH 
CORONARY HEART DISEASE COMORBIDITY  
Besides having a lipid controlling effect, statin can also play a role as an anti-
inflammatory agent. Some studies have conducted that patients  who consume statin 
show lower C-Reactive Protein (CRP) levels than the groups who do not receive statin 
therapy. (12)  
The clinical deterioration in COVID-19 is caused by cytokine storm phenomenon 
that involves IL-6, TNF-α, IL-1β, and other pro-inflammatory cytokines (4)(5). Statin has 
the potency in reducing the level of  pro-inflammatory cytokines  and improving the 
clinical outcomes in COVID-19 patients through several mechanism. (11) Statin can 
reduce cytokines storm in COVID-19 patients by normalizing the expression of Myeloid 
differentiation primary response 88 (MyD88) gene which is the result of the interaction of 
SARS-CoV  with Toll Like Receptor (TLR). The interaction of SARS-CoV with Toll Like 
Receptor (TLR) will activate NF-κB signaling pathway that will trigger the production of 
some pro-inflammatory cytokines. (22) Furthermore,  statin can inhibit the progression of 
elevated pro-inflammatory levels (IL-6, TNF-α, IL-10, dan IL-8) in some cells such as 
mononuclear cells, synovial cells, and endothelial cells.(23) Through these two 
mechanism, statin can be an effective reductor for cytokine storm that causes acute 
respiratory distress syndrome (ARDS) in COVID-19, especially for patients with coronary 
heart disease.  
 
3.5. ROLE OF STATIN IN INHIBITING TISSUE DAMAGE AND ENDOTHELIAL 
DISFUNCTION IN COVID-19 PATIENTS WITH CORONARY HEART 
DISEASE 
Aside from controlling lipid profile and suppressing the inflammation, statin also 
have the ability to inhibit tissue damage that happens in COVID-19 by binding to Mpro, 
a molecule protease produced by SARS-COV-2.(12)  
Invasion of SARS COV-2 can generate endothelial dysfunction due to its binding 
to the ACE-2 receptor in various organs.(24) Statin can improve the endothelial 
dysfunction by depressing the amount of adhesion molecules such as Intercellular 
Adhesion Molecule-1 (ICAM-1) and E-selectin; reducing the attachment of platelets dan 
leukocytes to the endothelial cells. These mechanisms will maintain the function of 
endothelium and improve the clinical outcomes of COVID-19 patients with coronary heart 
disease.  (25) (26) 
Statin can also act as an antioxidant that is important for restoring vascular redox 
balance that is initiated by the inflammatory process of COVID-19, this is based on the 
ability of statin to decrease redox-sensitive proinflammatory transcription factors like 
Nuclear Factor Kappa B (NF-κB).  (27)  Reactive oxygen species (ROS) has a negative 
impact to cardiac structure that can lead to contractility dysfunction, myocardial 
hypertrophy and fibrosis. Statin can reduce the production of ROS by suppressing the 
expression of  miRNA-221 and miRNA-222 and promoting BH4 cofactor, which relates 
to endothelium nitric oxide synthase 3 (eNOS). Moreover, disrupted blood flow that is 
caused by atherosclerotic plaque can enhance ROS by increasing endothelium shear 
stress and stimulating Krüppel-like Factor 2 (KLF-2) and activating cystathionine-lyase 
(CSE). Statin can also suppress the production of ROS by normalizing blood flow in 
blood vessels. (37) (38) (39) 
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Statin can also regulate some molecular pathways that control the activity of 
adenine dinucleotide phosphate oxidase and endothelium nitric oxide synthase which 
can help repairing the redox homeostasis. (38)   
Other mechanism of statin in inhibiting tissue damage and endothelial 
dysfunction is impairing NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) 
inflammasome, that is potent pro-inflammatory structures in endothelium cells, by 
stimulating pregnane X receptor (PXR). By this way, statin will prevent tissue damage 
and maintain the endothelial function. (39) 
Regeneration process becomes very important when endothelium damage 
happens as the result of severe tissue damage. This regeneration process is supported 
by endothelium progenitor cell (EPC) that will replace damaged cells naturally and have 
important role in preventing and treating cardiovascular disease. Statin has the ability to 
increase EPC as its pleiotropic effects. (39) 
In addition, statin is able to reduce oxidized LDL. That supports the reduction of 
LDL atherogenicity. These antioxidant and LDL-lowering effects of statin will support 
tissue repair in COVID-19 patients with coronary heart disease. (37)  
 
3.6.  POTENTIAL OF ROSUVASTATIN IN CLINICAL IMPROVEMENT OF COVID-
19 PATIENTS WITH CORONARY HEART DISEASE  
The effect of statin in improving clinical outcomes of COVID-19 patients is 
supported by a study in China that conducted a trial of statin administration to 13,981 
COVID-19 patients. The result of the study showed decreased C Reactive Protein (CRP), 
IL-6, and neutrophil level in statin group compared to control group. The decreased pro-
inflammatory cytokines will effect the symptoms that associate to high inflammatory 
process which caused by COVID-19 such as fever, cough, fatigue, and all severe 
symptoms such as shortness of breath, respiratory distress syndrome, and other signs 
of severe pneumonia. This evidence proves the effectiveness of statin as an anti-
inflammatory agent for COVID-19 patients. This mechanism is crutial to prevent the 
rupture of atherosclerotic plaque and the formation of thrombus due to aggrasive 
inflammation in COVID-19 patients with coronary heart disease. (42)   
A study conducted by Zhang et al in China, shows shorter length of hospital stay, 
low demand for mechanical ventilation and intensive care unit (ICU)  in statin group 
compared to control group. (28)  This finding indicates the ability of statin in inhibiting the 
progression of COVID-19 directly by inhibiting viral replication with the inhibision 
mechanism of SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA 
polymerase (RdRp) . Statins also can inhibit the progression of COVID-19 indirectly by 
its immunomodulatory effects, such as balancing the inflammation response by 
decreasing IL-6 via TLR-4, repairing endothelium function, as well as its lipid stabilizing 
effect by preventing the rupture of atherosclerotic plaque and the formation of thrombus 
due to the aggressive inflammation. (39) (40) (41) 
Furthermore, statin can also enhance the  immune response of macrophage that 
can be beneficial to ward off Macrophage Activation Syndrome (MAS), that is common 
in COVID-19 and causes hyperproduction of pro-inflammatory cytokines and can induce 
thrombosis. By optimizing the function of macrophage, statin can reduce the risk of 
thrombosis in COVID-19 by suppressing PAI-1 level in serum. Moreover, pulmonary 
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fibrosis can also be suppressed by statin with its ability in supressing TGF-β signaling 
pathway. (39)  
Statin is one of pharmacological therapy that can improve clinical outcomes, 
reduce the demand of mechanical ventilator  and shorten the length of hospital stay for 
COVID-19 patients with coronary heart disease based on some previous described 
mechanisms of statin.  
In order to compare several types of statins on reducing LDL levels, Y J Jeong et 
al conducted a clinical trial that shows the performance of rosuvastatin is significantly 
more effective in lowering LDL cholesterol compared to other statins in low-intensity 
statins , moderate-intensity statins, and moderate to high intensity statins such as 
atorvastatin, simvastatin, pitavastatin, dan pravastatin as listed in tabel 1. (29) 
Željko Reiner et al conducted a study in 2020 to compare the binding affinity 
between several statins and SARS COV-2 Mpro. Statins that involved in the study were 
rosuvastatin, pravastatin, simvastatin, pitavastatin, lovastatin, fluvastatin, and 
atorvastatin. The method of the study was in vitro molecular docking test. The result of 
the study shows that pitavastatin, rosuvastatin, and fluvastatin have stronger binding 
affinity compared to other statins.(12)    
Tabel 1. Comparation of LDL-lowering efficacy of statins 
 
 










Table 2. Comparations of statins’ binding affinity to SARS-CoV-2 Mpro and its amount of binding 
interaction 








1. Pitavastatin -8,2 2 
2 Fluvastatin -7,7 2 
3. Rosuvastatin -7,7 7 
4. Lovastatin -7,4 2 
5. Simvastatin -7.0 2 
6. Atorvastatin -6.8 3 
7. Pravastatin -6.6 4 
 
 
Source: Willim HA, Ketaren I, Supit AI. e-CliniC [Internet]. 2020;8(28):237–45.  
 
Based on previous research results, it can be concluded that rosuvastatin is 
potential to improve clinical outcomes in COVID-19 patients with coronary heart disease 
through its multiple ability to significantly reduce the level of LDL, to prevent tissue 
damage by its high-binding affinity to SARS-CoV-2 Mpro, to suppress cytokine storm, 
and to repaire endothelial dysfunction comparing to other statins. Therefore, based on 
these potential mechanisms, we recommend the use of rosuvastatin as a treatment for 
COVID-19 patients with coronary heart disease.   
4. CONCLUSION 
 This literature review elucidates the role of statins as lipid stabilizer in coronary 
heart disease patients, cytokine storm suppressor, and SARS-CoV-2 Mpro binder, and 
its contribution in improving endothelial function in COVID-19 patients. This review also 
conclude that rosuvastatin was superior to other statin in reducing LDL level and 
reinforcing binding affinity to SARS-CoV-2 Mpro. Based on these reasons, rosuvastatin 
is potential to be a propitious treatment approach for COVID-19 patients with coronary 
heart disease. Therefore, further in vivo research related to the use of rosuvastatin in 
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